Detection of Antimalarial Resistance-Associated Mutations in Plasmodium falciparum via a Platform of Allele-Specific PCR Combined with a Gold Nanoparticle-Based Lateral Flow Assay

Cheng, Weijia; Wang, Wei; Zhu, Huiyin; Song, Xiaonan; Wu, Kai; Li, Jian

doi:10.1128/spectrum.02535-22

Cited by 2 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result, the use of Au in the treatment of tropical human diseases is significant. For instance, the specificity of this diagnostic method is increased and improved when AuNPs are utilised in a polymerase chain reaction [35] . In schistosomiasis, AuNPs administered intraperitoneally can lessen the overall worm population, the number of liver eggs, and the size of granulomas in mice infected with S. mansoni.…”

Section: Metallic Nanoparticlesmentioning

confidence: 99%

Expanding the Frontiers of Schistosomiasis Treatment: The Promise of Nanoparticle Based Therapies

Raghavan

2023

Preprint

View full text Add to dashboard Cite

Schistosomiasis is one of the most neglected parasitic diseases in the world. The new neglected tropical diseases road map 2021–2030, adopted by the World Health Assembly, set global goals for the elimination of schistosomiasis. The current treatment options like praziquantel for schistosomiasis are limited. This review on nanoparticle-based treatments for schistosomiasis explores various upcoming technologies. Nanoparticle-based treatments and vaccines have emerged as a promising approach to overcome praziquantel therapeutic limitations by providing targeted and sustained delivery of drugs. Using the literature databases, the search was performed using the syntax Schistosoma, praziquantel, and schistosomiasis. nanoparticles, published between 2010- 2023. The bibliometric analysis showed that there has been a decline in the number of research reports and clinical trials in recent years. With increased funding and collaboration, this technology can be used to develop safe, effective, and affordable treatments that can save millions of lives. Our discussion wants to raise awareness and advocate for increased support for nanoparticle-based research and development for this neglected tropical disease.

show abstract

Section: Metallic Nanoparticlesmentioning

confidence: 99%

Expanding the Frontiers of Schistosomiasis Treatment: The Promise of Nanoparticle Based Therapies

Raghavan

2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Now, pregnancy test LFA is widely used for home pregnancy tests worldwide. Due to the low development cost and faster turnaround time, many studies have used the nucleic acid LFA method as a diagnostic tool to diagnose disease and genotype drug-resistance genes involved in infectious diseases ( 15 – 20 ).…”

Section: Introductionmentioning

confidence: 99%

Development of DNA-Based Lateral Flow Assay for Detection of LDLR Gene Mutation for Familial Hypercholesterolemia

Saidi,

Md Rani,

Sulaiman

et al. 2024

MJMS

View full text Add to dashboard Cite

Background: The techniques for detecting single nucleotide polymorphisms (SNP) require lengthy and complex experimental procedures and expensive instruments that may only be available in some laboratories. Thus, a deoxyribonucleic acid (DNA)-based lateral flow assay (LFA) was developed as a point-of-care test (POCT) diagnostic tool for genotyping. In this study, single nucleotide variation (E101K) in the low-density lipoprotein receptor (LDLR) gene leading to familial hypercholesterolemia (FH) was chosen as a model. Methods: Hypercholesterolemic individuals (n = 103) were selected from the Malaysian Cohort project (UKM Medical Molecular Biology Institute) while the control samples were selected from the Biobank (UKM Medical Molecular Biology Institute). The DNA samples were isolated from whole blood. Polymerase chain reaction (PCR) amplification process was performed using bifunctional labelled primers specifically designed to correspond to the variant that differentiates wild-type and mutant DNA for visual detection on LFA. The variant was confirmed using Sanger sequencing, and the sensitivity and specificity of the LFA detection method were validated using the Agena MassARRAY® technique. Results: Out of 103 hypercholesterolemic individuals, 5 individuals (4.8%) tested positive for E101K, LDLR mutation and the rest, including healthy control individuals, tested negative. This result was concordant with Sanger sequencing and Agena MassARRAY®. These five individuals could be classified as Definite FH, as the DNA diagnosis was confirmed. The sensitivity and specificity of the variant detection by LFA is 100% compared to results using the genotyping method using Agena MassARRAY®. Conclusion: The developed LFA can potentially be used in the POC setting for detecting the E101K variant in the LDLR gene. This LFA can also be used to screen family members with E101K variant in the LDLR gene and is applicable for other SNP’s detection.

show abstract

Detection of Antimalarial Resistance-Associated Mutations in Plasmodium falciparum via a Platform of Allele-Specific PCR Combined with a Gold Nanoparticle-Based Lateral Flow Assay

Cited by 2 publications

References 29 publications

Expanding the Frontiers of Schistosomiasis Treatment: The Promise of Nanoparticle Based Therapies

Expanding the Frontiers of Schistosomiasis Treatment: The Promise of Nanoparticle Based Therapies

Development of DNA-Based Lateral Flow Assay for Detection of LDLR Gene Mutation for Familial Hypercholesterolemia

Contact Info

Product

Resources

About